hackint0sh/New-Dataset huggingface dataset:
Missing data for baseline characteristics will be assessed and addressed as a categorical variable with a level for missingness. All reported measures will be summarized in the study tables. Point estimates and their 95% CIs will be presented in the final analyses. conditions: Neurofibromatosis 1 conditions: Plexiform Neurofibroma studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: RETROSPECTIVE count: 2000 type: ESTIMATED name: This study is purely descriptive study. measure: Determine the percentage of NF1 patients developed PN at the baseline. measure: Clinical characteristics of NF1-PN: measure: Tumor progression of NF1-PN measure: Treatment pattern of NF1-PN: measure: The exploratory endpoints: sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Xuanwu Hospital, Capital Medical University status: RECRUITING city: Beijing state: Beijing country: China name: Lei Zhang role: CONTACT phone: +86 13683139858 email: zhanglei@xwhosp.org lat: 39.9075 lon: 116.39723 facility: The First Affiliated Hospital of Guangxi Medical University status: RECRUITING city: Nanning state: Guangxi country: China name: Jiping Shi role: CONTACT phone: +86 17758670856 lat: 22.81667 lon: 108.31667 facility: The First Affiliated Hospital of Zhengzhou University status: RECRUITING city: Zhengzhou state: Henan country: China name: Minjing Chen role: CONTACT phone: +86 13673665337 email: 1916833431@qq.com lat: 34.75778 lon: 113.64861 facility: Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine status: ACTIVE_NOT_RECRUITING city: Shanghai state: Shanghai zip: 200011 country: China lat: 31.22222 lon: 121.45806 facility: West China Hospital, Sichuan University status: RECRUITING city: Chengdu state: Sichuan country: China name: Yang Xiao role: CONTACT phone: +86 18884266797 email: xiaoyang_angela@163.com lat: 30.66667 lon: 104.06667 hasResults: False
nctId: NCT06379217 id: CAAA617H12101 id: 2023-505655-43 type: EUDRACT_NUMBER briefTitle: NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer. overallStatus: NOT_YET_RECRUITING date: 2024-06-18 date: 2027-06-04 date: 2027-06-04 date: 2024-04-23 date: 2024-04-23 name: Novartis Pharmaceuticals class: INDUSTRY briefSummary: The purpose of this study is to evaluate the change in the expression of treatment targets on the surface of tumor cells (Prostate Specific Membrane Antigen (PSMA), Somatostatin Receptor 2 (SSTR2), and Gonadotropin Releasing Hormone Receptor (GRPR)) between the start and after the completion of radioligand therapy (RLT). Study will use radioligand imaging (RLI) to determine predominantly expressed target on the surface of tumor cells. Based on predominant expression of target, corresponding RLT targeting PSMA, SSTR2, or GRPR RLT will be given for up to 6 cycles every 6 weeks as intravenous (i.v.) injection in participants with metastatic neuroendocrine prostate cancer (mNEPC). conditions: Metastatic Neuroendocrine Prostate Cancer studyType: INTERVENTIONAL phases: PHASE1 allocation: NON_RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Participants will be assigned to a treatment arm based on their predominantly expressed target per PET images (based on central read):
* \[177Lu\]Lu-NeoB will be assigned to those with predominant GRPR expression primaryPurpose: TREATMENT masking: NONE count: 36 type: ESTIMATED name: [68Ga]Ga-PSMA-11 name: [68Ga]GA-DOTA-TATE name: [68Ga]Ga-NeoB name: [177Lu]Lu-PSMA-617 name: [177Lu]Lu-DOTA-TATE name: [177Lu]Lu-NeoB name: L-Lysine HCl-L-Arginine HCl, 2.5 %, name: Gonadotropin-releasing hormone (GnRH) analogues name: GnRH antagonists name: Antiemetics & antinauseants name: Metoclopramide measure: Number/extent of lesions with at least a moderate uptake of any of the Radioligand Imaging (RLI) measure: Percentage changes in qualitative PET parameters. measure: Overall Response Rate (ORR) measure: Disease Control Rate (DCR) measure: Duration of response (DOR) measure: Radiographic Progression-free Survival (rPFS) measure: Proportion of participants with a decline in PSA level measure: Incidence and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs) for Radioligand Therapy (RLT) measure: Dose modifications for [177Lu]Lu-PSMA-617, [177Lu]Lu-DOTA-TATE and [177Lu]Lu-NeoB measure: Incidence and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs) for Radioligand Imaging (RLI) measure: Blood radioactivity concentration of [177Lu]Lu-PSMA-617, [177Lu]Lu-DOTA-TATE, [177Lu]Lu-NeoB) measure: Blood mass concentration of [177Lu]Lu-PSMA-617, [177Lu]Lu-DOTA-TATE, [177Lu]Lu-NeoB) measure: Observed maximum blood concentrations (Cmax) of [177Lu]Lu-PSMA-617, [177Lu]Lu-DOTA-TATE and [177Lu]Lu-NeoB measure: Time of maximum blood concentration (Tmax) occurence of [177Lu]Lu-PSMA-617, [177Lu]Lu-DOTA-TATE and [177Lu]Lu-NeoB measure: Area under the blood concentration time curve (AUC) of [177Lu]Lu-PSMA-617, [177Lu]Lu-DOTA-TATE and [177Lu]Lu-NeoB measure: Total systemic clerance (CL) of [177Lu]Lu-PSMA-617, [177Lu]Lu-DOTA-TATE and [177Lu]Lu-NeoB measure: Volume of distribution during the terminal phase (Vz) of [177Lu]Lu-PSMA-617, [177Lu]Lu-DOTA-TATE and [177Lu]Lu-NeoB measure: Terminal half-life (T^1/2) of [177Lu]Lu-PSMA-617, [177Lu]Lu-DOTA-TATE and [177Lu]Lu-NeoB measure: Absorbed radiation doses of [177Lu]Lu-PSMA-617, [177Lu]Lu-DOTA-TATE and [177Lu]Lu-NeoB measure: Time Activity Curves (TACs) of [177Lu]Lu-PSMA-617, [177Lu]Lu-DOTA-TATE and [177Lu]Lu-NeoB sex: MALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06379204 id: No.2022026 briefTitle: A Study on the Intervention of Metabolic Syndrome Patients With Exercise Prescription Based on Ventilatory Threshold Using Cardiopulmonary Exercise Test overallStatus: COMPLETED date: 2022-11-04 date: 2023-08-30 date: 2023-09-19 date: 2024-04-23 date: 2024-04-26 name: Taiyuan Central Hospital of Shanxi Medical University class: OTHER briefSummary: Analyze the clinical intervention effects and differences of progressive precision exercise prescriptions formulated by two methods for determining exercise intensity on metabolic syndrome (MS). Compare the effects of the two on the cardiovascular endurance of the MS population and verify the effectiveness of individualized methods in reducing absolute exercise intensity for MS patients. conditions: Metabolic Syndrome X studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 52 type: ACTUAL name: the maximum physiological value standardized group name: the ventilatory threshold individualized group measure: Peak oxygen uptake sex: ALL minimumAge: 25 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Taiyuan Cardiac Rehabilitation Center city: Taiyuan state: Shanxi zip: 030009 country: China lat: 37.86944 lon: 112.56028 hasResults: False
nctId: NCT06379191 id: ZS-3411 briefTitle: The Efficacy of WeChat-based Multidisciplinary Full-course Nutritional Management Program overallStatus: COMPLETED date: 2023-02-01 date: 2023-10-30 date: 2023-10-30 date: 2024-04-23 date: 2024-04-23 name: Peking Union Medical College Hospital class: OTHER briefSummary: As the most malignant type of cancer in the female reproductive system, ovarian cancer (OC) has become the second leading cause of death among Chinese women. Chemotherapy is the main treatment for OC patients, and its numerous adverse effects can easily lead to malnutrition. It is difficult to centrally manage OC patients in the intervals between chemotherapy. The utility of WeChat, an effective and more cost-efficient mobile tool, in chronic disease management has been highlighted. conditions: Ovarian Cancer studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: HEALTH_SERVICES_RESEARCH masking: NONE count: 78 type: ACTUAL name: Nutrition intervention model based on WeChat applets measure: patient-generated subjective global assessment (PG-SGA) measure: nutrition-related blood indices, such as total protein (g/L), albumin (g/L), prealbumin (g/L), and hemoglobin (g/L) measure: inflammation-related blood indices, such as leukocytes (10^9/L), lymphocytes (10^9/L), neutrophils (10^9/L), and platelets (10^9/L) measure: nutrition-inflammation composite indices, such as prognostic nutritional index (PNI) and systemic immunoinflammatory index (SII) sex: FEMALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Peking Union Medical College Hospital, Chinese Academy of Medical Sciences city: Beijing state: Beijing country: China lat: 39.9075 lon: 116.39723 hasResults: False
nctId: NCT06379178 id: 6462e56fe8177 briefTitle: Effect of Oral Colostrum Applications Every 2 Hours and 4 Hours In Order to Achieve Trophic Feeding in Preterm Infants overallStatus: COMPLETED date: 2023-02-19 date: 2023-08-15 date: 2023-08-31 date: 2024-04-23 date: 2024-04-23 name: Gadjah Mada University class: OTHER briefSummary: The goal of this clinical trial is aims to evaluate the effects of applying colostrum orally every 4 and 2 hours in order to achieve trophic feeding in preterm infants. The main question it aims to answer is the optimal frequency of colostrum application that can be applied Participants will be divided by randomization using permutation blocks after meeting the inclusion and exclusion criteria and deemed eligible. These blocks were then randomized using computer software such as Microsoft Excel, determining the sequence for allocation to the control and intervention groups based on the randomization order from the permutation code, every 2 hours and every 4 hours. Researchers will investigate the effects of oropharyngeal colostrum application frequency, every 4 hours and every 2 hours, in order to achieve trophic feeding in preterm infants \<34 weeks gestational age. conditions: Trophic Feeding conditions: Very Low Birth Weight Baby conditions: Preterm studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 47 type: ACTUAL name: Oral colostrum application 2 hours name: Oral colostrum application 4 hours measure: Days to Achieve Trophic Feeding sex: ALL maximumAge: 2 Days stdAges: CHILD facility: Neonatal Intensive Care Unit RSUP Dr. Sardjito city: Sleman state: Daerah Istimewa Yogyakarta zip: 55281 country: Indonesia lat: -7.71556 lon: 110.35556 hasResults: False
nctId: NCT06379165 id: SYH9015-002 briefTitle: Efficacy and Safety Study of Meloxicam Nanocrystal Injection for the Treatment of Moderate to Severe Pain overallStatus: COMPLETED date: 2023-05-17 date: 2023-07-11 date: 2023-07-13 date: 2024-04-23 date: 2024-04-23 name: CSPC ZhongQi Pharmaceutical Technology Co., Ltd. class: INDUSTRY briefSummary: The purpose of this study is to evaluate the efficacy and safety of meloxicam nanocrystal injection in subjects with moderate to severe pain after abdominal surgery. conditions: Pain studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 192 type: ACTUAL name: Meloxicam Nanocrystal Injection name: Placebo measure: PID24 (Time Weighted Sum of Pain Intensity Difference Over 24 Hours Post-Dose) measure: TOTPAR (time-weighted sum of pain relief scores): TOTPAR12, TOTPAR18, TOTPAR24, TOTPAR48. measure: SPID2、SPID6、SPID12、SPID18、SPID18-24、SPID24-48、SPID42-48、SPID48 measure: Time to the first dose of the remedial analgesia measure: Number of times of remedial analgesia administered 0-24h and 24-48h after the first dose measure: Proportion of subjects requiring remedial analgesia measure: The total amount of remedial analgesia used 24 h and 48 h after the first dose measure: The subject's analgesic treatment satisfaction score (0-4 point categorical scale score) measure: The investigator's satisfaction score (0-4 point categorical scale score) for the subject's analgesic treatment sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Union Hospital of Tongji Medical College of Huazhong University of Science and Technology city: Wuhan country: China lat: 30.58333 lon: 114.26667 hasResults: False
nctId: NCT06379152 id: 2024-04-16 briefTitle: Effect of Bilirubin on Prognosis in Heart Failure With Preserved Ejection Fraction overallStatus: RECRUITING date: 2020-09-20 date: 2024-06-30 date: 2024-07-01 date: 2024-04-23 date: 2024-04-23 name: Chongqing Medical University class: OTHER briefSummary: Factors influencing the prognosis of patients with heart failure with preserved ejection fraction (HFpEF) have been extensively studied. Previous studies have found that elevated serum total bilirubin levels are associated with cardiac death, heart failure readmission, and all-cause mortality in patients with chronic heart failure. However, the relationship between direct bilirubin and prognosis in patients with HFpEF is unclear. conditions: Heart Failure With Preserved Ejection Fraction conditions: Prognathism studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 400 type: ESTIMATED measure: The level of direct bilirubin measure: a composite of heart failure rehospitalization or all-cause mortality measure: heart failure rehospitalization measure: all-cause mortality sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: The First Affiliated Hospital of Chongqing Medical University status: RECRUITING city: Chongqing country: China name: Dongying Zhang, doctor role: CONTACT phone: +8613608398395 email: zdy.chris@qq.com lat: 29.56278 lon: 106.55278 hasResults: False
nctId: NCT06379139 id: MALDINEY J'InvEst-I 2022 briefTitle: Dynamic Full-field Optical Coherence Tomography for Structural and Microbiological Characterization of Endotracheal Tube Biofilm in Critically Ill Patients acronym: BIOPAVIR2 overallStatus: RECRUITING date: 2024-03-01 date: 2025-03 date: 2025-03 date: 2024-04-23 date: 2024-04-23 name: Centre Hospitalier Universitaire Dijon class: OTHER briefSummary: Biofilm is a microstructure organised into aggregates of microbiological species within a polymeric matrix. As early as the 2000s, the Centers for Disease Control and Prevention (CDC) recognised the possible role of the biofilm lining endotracheal endotracheal tubes in the development of ventilator-associated pneumonia (VAP) , the most common infection in intensive care, with a high morbidity and mortality rate and a significant increase in hospital costs.
To this end, the investigator carried out an initial clinical study describing the biofilm on intubation probes, BIOPAVIR 1, showing the existence of several biofilm structures, each associated with a specific microbiological signature. Several limitations including a lack of power due to an insufficient number of patients and the use of number of patients, and the use of a confocal microscopy technique with poor axial without the possibility of acquiring metabolic images of the biofilm.
Based on the previous description of biofilm by optical coherence tomography (OCT), and a recent experience with an optimised form of high-resolution OCT, called full-field OCT, the investigator hypothesise that full-field OCT will allow more accurate characterisation of biofilm, due to its high spatial resolution and its potential ability to capture metabolic activity in the biofilm BIOPAVIR 2 proposes to use the performance of full-field OCT to better characterise the biofilm lining endotracheal tubes in patients undergoing mechanical ventilation in intensive care units. This project represents a first step towards understanding the link between the development of biofilm on intubation and the occurrence of VAP conditions: Healthcare Associated Infection conditions: Critically Ill conditions: Endotracheal Tube studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 80 type: ESTIMATED name: •Dynamic Full-Field Optical Coherence Tomography analysis of endotracheal tube measure: Dynamic Full-Field Optical Coherence Tomography-based biofilm structure type measure: type of microbiological associated with each shape sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: CH William Morey status: RECRUITING city: Chalon-sur-Saône country: France name: Thomas MALDINEY role: CONTACT email: thomas.maldiney@ch-chalon71.fr lat: 46.78333 lon: 4.85 facility: CHU Dijon Bourgogne status: RECRUITING city: Dijon country: France name: Jean Pierre QUENOT role: CONTACT email: jean-pierre.quenot@chu-dijon.fr lat: 47.31667 lon: 5.01667 hasResults: False
nctId: NCT06379126 id: Yuting Li05 briefTitle: The Diagnostic and Prognostic Value of TAT, PIC, tPAI·C and TM in Sepsis-induced Coagulopathy overallStatus: NOT_YET_RECRUITING date: 2024-04-20 date: 2026-04-20 date: 2026-04-20 date: 2024-04-23 date: 2024-04-23 name: The First Hospital of Jilin University class: OTHER briefSummary: In order to evaluate the diagnostic and prognostic value of thrombin-antithrombin complex（TAT）, α2-plasmin inhibitor-plasmin complex（PIC）, tissue plasminogen activator-inhibitor complex（tPAI·C） and thrombomodulin（TM） in sepsis-induced coagulopathy(SIC), hospitalized patients with sepsis were prospectively included. Plasma TAT, PIC, tPAI·C,TM levels within 24 h after sepsis diagnosis were detected by MCL60 chemiluminescence analyzer. According to the SIC score (≥4), they were divided into SIC group and non-SIC group, and ROC curve analysis was performed according to the biomarker test results. conditions: Sepsis-induced Coagulopathy studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 210 type: ESTIMATED name: Test thrombin-antithrombin complex（TAT）, α2-plasmin inhibitor-plasmin complex（PIC）, tissue plasminogen activator-inhibitor complex（tPAI·C） and thrombomodulin（TM） measure: Thrombin-antithrombin complex（TAT）, α2-plasmin inhibitor-plasmin complex（PIC）, tissue plasminogen activator-inhibitor complex（tPAI·C） and thrombomodulin（TM） level sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06379113 id: 53211030-2 briefTitle: GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Cancer Patients overallStatus: RECRUITING date: 2022-07-13 date: 2025-03-30 date: 2025-03-30 date: 2024-04-23 date: 2024-04-23 name: Xiaojun Chen class: OTHER briefSummary: To investigate the efficacy of GnRHa plus letrozole in obese progestin-insensitive EEC patients. conditions: Endometrial Neoplasms conditions: Atypical Endometrial Hyperplasia conditions: Progesterone Resistance conditions: Obesity studyType: INTERVENTIONAL phases: PHASE2 phases: PHASE3 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 29 type: ESTIMATED name: GnRH antagonist name: Letrozole 2.5mg measure: Complete response rates within 28 weeks of treatment measure: Adverse events measure: Time to achieve complete response measure: Relapse rates measure: Rates of fertility outcomes measure: Compliance sex: FEMALE minimumAge: 18 Years maximumAge: 45 Years stdAges: ADULT facility: Obstetrics and Gynecology Hospital, Fudan University status: RECRUITING city: Shanghai country: China name: Xiaojun Chen role: CONTACT phone: 862133189900 email: cxjlhjj@163.com lat: 31.22222 lon: 121.45806 hasResults: False
nctId: NCT06379100 id: KY20232388 briefTitle: Cerebellar iTBS Mode Transcranial Magnetic Stimulation for the Treatment of Alzheimer's Disease overallStatus: NOT_YET_RECRUITING date: 2024-04-25 date: 2024-08-25 date: 2024-09-25 date: 2024-04-23 date: 2024-04-23 name: Xijing Hospital class: OTHER briefSummary: Study the therapeutic effect and potential neural mechanisms of cerebellar iTBS mode transcranial magnetic stimulation on Alzheimer's disease patients through MRI and EEG. conditions: Transcranial Magnetic Stimulation conditions: Alzheimer Disease conditions: Magnetic Resonance Imaging conditions: Electroencephalogram studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: TRIPLE maskingDescription: Alzheimer's disease patients were enrolled by expert neurol ogists who were blinded to treatment allocation. rTMS sessions were performed by dedicated technicians. The Cognitive evaluations and analysis of neuro physiological data were performed by expert neurophysiologists blinded to treatment allocation. whoMasked: PARTICIPANT whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 28 type: ESTIMATED name: transcranial magnetic stimulation measure: The changes in CDR（Clinical Dementia Rating） measure: The changes in MMSE(Mini Mental State Examination) measure: NPI (Neuropsychiatric Inventory) measure: ADL( Lawton-Brody Activities of Daily Living) measure: DST (Digital Span Test; Forward and Backward) measure: ADAS-cog（Alzheimer's disease assessment scale) measure: DMS(Delayed matching-to-sample task) measure: MEP（Motor evoked potential） measure: MRI measures measure: EEG（electroencephalogram） sex: ALL minimumAge: 45 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Xijing Hospital of Air Force Military Medical University city: Xi'an state: Shaanxi zip: 710032 country: China name: Wen Jiang role: CONTACT phone: 13991905538 email: jiangwen@fmmu.edu.cn name: Xin Zhang role: CONTACT phone: 13154378732 email: zx312316@163.com lat: 34.25833 lon: 108.92861 hasResults: False
nctId: NCT06379087 id: NEO-PIONEER briefTitle: Radiation Therapy Followed by Tislelizumab and Anlotinib Aeoadjuvant/Adjuvant Therapy for Stage II-IIIA NSCLC overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2025-12-31 date: 2026-12-31 date: 2024-04-23 date: 2024-04-25 name: Ji Yongling class: OTHER briefSummary: This study is a single-center, prospective, single-arm exploratory clinical study of hypofractionated radiotherapy followed by tislelizumab and anlotinib neoadjuvant and adjuvant therapy. It is designed for patients with stage II-IIIA non-small cell lung cancer. The efficacy and safety of hypofractionated radiotherapy sequential tislelizumab and anlotinib in the neoadjuvant and adjuvant treatment of stage II-IIIA non-small cell lung cancer are observed. Finally, it provides new evidence-based medical evidence for the perioperative treatment of non-small cell lung cancer. conditions: Non-Small Cell Lung Cancer studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 20 type: ESTIMATED name: Anlotinib Hydrochloride Capsule name: Tislelizumab Injection name: Hypofractionated Radiotherapy measure: 1-year EFS Rate measure: pCR Rate measure: MPR Rate measure: Adverse Events (AEs) according to CTCAE (V5.0) (Safety Evaluation) sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False